

ROCE Fund

Year ending December 31st, 2024

Commentary

05 February 2025

Dear investors,

In September 2020, just over 4 years ago, we launched ROCE Fund. This is our second annual letter, serving as a more detailed supplement to our monthly reports. The letter encompasses the performance and activities of ROCE Fund throughout 2024, along with our current positioning and insights into 2025.

The table below shows performance figures of ROCE Fund and various benchmarks and comparators for each calendar year as well as the cumulative performance since our inception on September 28th, 2020.

Yearly performance v benchmarks and peers²

Year	2020*	2021	2022	2023	2024	Since inception	Annualized
ROCE Fund (G)¹	**16.6%**	**21.3%**	**(10.0%)**	**22.1%**	**3.5%**	**61.0%**	**11.8%**
MSCI Europe Total Return	10.0%	25.1%	(9.5%)	15.8%	8.6%	57.7%	11.3%
Outperformance/(under)	*6.6%*	*(3.8%)*	*(0.5%)*	*6.3%*	*(5.1%)*	*3.3%*	*0.5%*
MSCI Europe Mid Total Returr	17.4%	23.8%	(22.5%)	12.7%	5.7%	34.1%	7.1%
Outperformance/(under)	*(0.7%)*	*(2.5%)*	*12.5%*	*9.4%*	*(2.1%)*	*26.9%*	*4.7%*
Peers' index²	10.6%	21.6%	(16.0%)	14.8%	5.4%	36.5%	7.6%
Outperformance²/(under)	*6.0%*	*(0.3%)*	*6.0%*	*7.3%*	*(1.9%)*	*24.5%*	*4.3%*
% peers beaten²	84%	47%	73%	97%	37%	87%	87%

¹ Share class G ; ² Peers' index defined by the average of 90 long only funds invested in European equities.
* 2020 includes performance from inception date (September 28th, 2020) until December 31st, 2020.

ROCE Fund returned 3.5%¹ in 2024, net of fees. Since inception in September 2020, ROCE Fund has delivered a total return of 61.0%¹ (11.8% annualized), net of fees, outperforming its benchmarks, as shown above. It also has beaten 87% of its European equity long-only peers² since inception.

2024 was a strong year for equity markets with MSCI Europe up 8.6%, and MSCI World up an impressive 27.5% in EUR terms driven by a particularly strong US market for the second year in a row.

ROCE Fund's performance fell short of expectations in 2024 and lagged its benchmarks. This underperformance was mainly driven by two factors: our exposure to (i) France and (ii) small and mid-cap stocks. We will take a closer look at each of these.

ROCE Fund's exposure to France

At the end of 2024, companies listed in France accounted for 42% of our portfolio, a notable overweight compared to MSCI Europe's 17%. This positioning weighed on our performance, as France was the worst-performing European market in 2024. This underperformance was sparked by President Macron's unexpected decision to call for new legislative elections in June 2024, which led to prolonged political unrest. The resulting uncertainty caused a sharp sell-off in the French stock market, from which it has yet to recover.



Source: Bloomberg. Data as of 31/12/2024

Our overweight exposure to companies listed in France is the result of our bottom-up approach which focuses on identifying quality names with high ROCE that are also trading at attractive valuations, rather than a bullish macro view on the French economy. The French stock market offers a greater number of companies that align with our investment criteria compared to many other regions, such as Switzerland, Germany or the Nordic countries, where quality often comes at steeper valuations. This is the primary reason behind our positioning, which has been consistent since our inception.

The market often misinterprets a company's geographic exposure based on its country of listing, rather than where it actually generates its sales and profits. It is essential to distinguish between our exposure to French-listed companies and our true economic exposure to France, as these are two separate concepts. Our true exposure to France—measured by the revenue-weighted percentage of the

portfolio—is only at just 15%. We believe this revenue-based measure offers a much more accurate reflection of a portfolio's true geographic exposure.

For instance, LVMH is listed in France and categorized as a *French investment*, yet only 8% of its sales originate there. Furthermore, most of its domestic sales are driven by tourists—primarily from the United States, China, and Japan. Ultimately, French consumers represent only 3% to 4% of LVMH's total sales. This highlights the need to prioritize revenue distribution over listing location when evaluating a portfolio's geographic exposure.

The charts below compare ROCE Fund's exposure based on the country of listing with its actual sales exposure, which we believe provides a more accurate representation of the fund's economic exposure by region. As shown, ROCE Fund is only 58% exposed to Europe while 42% of the portfolio's weighted sales are generated outside Europe, including 18% in the US and 25% in RoW (which includes Asia, Africa, Middle East & Latin America).



Source: ROCE Capital, Bloomberg, company data

The key takeaway we want to highlight for our investors is that, while ROCE Fund may optically seem heavily skewed heavily toward France due to its listing distribution, this perception is misleading. In reality, ROCE Fund has a much more global and balanced profile when assessed through its position-weighted sales geographic distribution.

We are, of course, mindful that French political unrest has weighed on sentiment, with many investors avoiding and even selling all companies listed in France following Macron's decision to call for new legislative elections. Our integration of top-down and macro analysis consists mainly of adopting a contrarian, and a patient approach. We are not afraid to invest in sectors or countries temporarily out of favor due to macroeconomic contexts, while also steering clear of trendy sectors experiencing heightened demand, such as artificial intelligence at present.

France has been particularly deeply out of favor during the second half of 2024, which, as noted earlier, has impacted our performance. However, it is precisely in France where we now see the most compelling opportunities offering the best risk-reward potential from a fundamental bottom-up perspective. As always, we are taking our usual contrarian and patient approach to position our investors to benefit from these attractive opportunities.

In time, the negative sentiment surrounding French politics will subside, and French stocks will begin to reflect their fundamentals more accurately. In fact, this trend has already started to emerge since the beginning of the year. We believe it will continue.

It is important to recognize that political unrest and governmental stagnation are not new challenges for France. For decades, the country has faced significant difficulties in implementing structural reforms, often encountering resistance from various stakeholders and navigating a deeply ingrained tradition of political pushback. Strikes, protests, and bureaucratic inertia have frequently slowed down progress on key reforms aimed at modernizing the economy.

Yet, despite these persistent challenges, the French stock market has consistently demonstrated resilience. Over the long term, it has managed to slightly outperform the MSCI Europe, as evidenced in the chart below. This highlights the underlying strength and adaptability of French companies, many of which are global leaders in their respective industries, capable of weathering domestic political turbulence while capitalizing on international growth opportunities.



Source: Bloomberg. Data as of 31/12/2024

<u>ROCE Fund's exposure to small & mid-caps</u>

European small & mid-caps currently appear undervalued after an unprecedented 4-year stretch of underperformance, trailing European large caps by approximately 30% cumulatively, as illustrated below. Unfortunately for us, 2024 continued this trend, further weighing on our returns. Our structural exposure to small & mid-caps was the other key factor that impacted our performance negatively in 2024.



Source: Bloomberg. Data as of 31/12/2024

The underperformance of small & mid-caps can be attributed to various factors, including the structural rise of ETFs and passive strategies, which predominantly focus on large caps. Additionally, the highly volatile macro environment since the onset of the COVID pandemic and the rapid increase in interest rates observed throughout 2023 have contributed to this trend.

We had hoped that the onset of interest rate cuts, which indeed materialized in 2024, would serve as a catalyst for a rebound in European small & mid-cap equities. However, this recovery has yet to take shape. Nevertheless, we remain firmly convinced that this asset class is both significantly undervalued and overlooked in today's market.

The behavior of market trends and asset class rotations, especially in segments like small & mid-caps, often defies short-term predictions. These movements are inherently unpredictable and demand patience and a long-term perspective to unlock their true potential. We are committed to staying the course, confident that the market will eventually recognize the substantial intrinsic value within this segment.

There is a growing concern among clients and investors about the potential revival, or lack thereof, of European small & mid-caps and whether this asset class is permanently impaired and destined for structural underperformance. We hold a different view and draw inspiration from Warren Buffet's wisdom to be "*greedy when others are fearful and fearful when others are greedy*." The fact that many investors have given up on European small & mid-caps is interpreted as a bullish signal by our team.

As illustrated in the chart below, European small & mid-caps, after 4 consecutive years of underperformance and de-rating, are now trading at an all-time discount of approximately 6% relative to large-caps— a stark contrast to their historical average premium of 12%. This significant shift in valuation suggests to us a growing investment opportunity.



Source: Bloomberg. Data as of 31/12/2024. P/E based on 12-month forward data. [1] Discount Small & Mids v Large calculated using the average of MSCI Europe P/E divided by the average of MSCI Europe Mid and MSCI Europe Small P/E.

Considering this perspective, we have marginally increased our exposure to small & mid-caps over the past 2 years, given their sustained underperformance, driven by our perception of their generally more appealing valuations compared to large caps. The chart below illustrates the breakdown of our portfolio's exposure based on market capitalization size since its inception.



	< €300M	€300M to €1bn	€1bn to €2bn	€2bn to €10bn	> €10bn	Cash
October 2020	5%	22%	10%	32%	27%	4%
December 2021	5%	20%	7%	36%	31%	1%
December 2022	0%	25%	7%	27%	35%	4%
December 2023	1%	22%	13%	37%	26%	1%
December 2024	1%	16%	28%	32%	25%	0%

Source: ROCE Capital

While we have marginally increased our exposure to small & mid-caps (defined as companies with market capitalizations below €10bn) over the past 24 months—particularly throughout 2023—it is important to remind our investors that we are a multi-cap fund with a mid-cap bias. Historically, our median market capitalization has fluctuated between approximately €3bn and €4bn, with our current median capitalization at €3.2bn.

Beyond the cyclical appeal of small and mid-caps following an unprecedented four years of underperformance, we also have a structural preference for this asset class for several key reasons:

i) Growing inefficiencies and opportunities – With declining sell-side coverage, small and mid-caps present attractive opportunities for skilled investors.
ii) Better access to management – Engaging with leadership teams is often easier and more transparent, allowing for deeper due diligence.
iii) Simpler business models – These companies are typically more straightforward and easier to analyze compared to larger, more complex organizations.
iv) Higher volatility – While often perceived as a risk, heightened volatility instead presents opportunities and fosters a dynamic environment where we thrive, leveraging our long-term investment approach to capitalize on market inefficiencies.

While small and mid-caps have underperformed large caps over the past decade, it is important to remember that, over the long term, they have historically delivered a slight outperformance, as shown below.



Source: Bloomberg. Data as of 31/12/2024

By no means is this letter an attempt to shift responsibility away from our underperformance in 2024. Our exposure to small & mid-caps, as well as French-listed equities, has always been an informed and deliberate investment strategy—one that we have maintained since our inception and strengthened going into 2024. Unfortunately, it worked against us again in 2024. We firmly believe, however, that these negative trends will ultimately reverse. With the best interests of our investors in mind, we will maintain our current positioning. We remain confident in our strategy and will stay the course, trusting that the long-term fundamentals will eventually prevail.

Perspectives for 2025

We believe that attempting to predict short-term market movements based on macro views is not only very difficult but also risky. At ROCE Capital, we dedicate minimal time to macroeconomic factors and, instead, prioritize company-specific, bottom-up analysis. Our strategy revolves around owning companies that generate high returns on capital employed ("ROCE") and trade at attractive valuations. We assert that excessive focus on attempting to predict market movements based on macro views can sometimes be counterproductive. Many market participants devote excessive time to forecasting the intricacies of macroeconomics, which we believe are inherently too complex. Such tactics often lead to heightened trading activity and are typically associated with long-term underperformance.

We endeavor to adhere to Charlie Munger's view that "*the stock market is a device for transferring money from the impatient to the patient.*" While this guidance is straightforward in theory, its implementation proves exceptionally challenging in the face of the relentless daily pressures investors encounter to conform to market sentiment and make impulsive trades driven by the latest macro-economic news. Munger and Buffett's patient and contrarian strategy has consistently proven effective across market cycles, producing superior results. The chart below serves as visual reminders of the potential pitfalls associated with market psychology. We make a concerted effort to remain mindful of these insights, keeping this chart prominently displayed on the walls of our office.



We have observed from a distance the wave of optimism that has swept through the markets, particularly in North America, following President Trump's election. Some share price movements, such as Tesla's, which has doubled during 2024 and is now trading at 170x its last twelve months' EBIT appear entirely disconnected from fundamentals. In our view, the US markets—especially the

NASDAQ—look overvalued. While it is unclear exactly where US tech investors stand on the sentiment cycle above, we would estimate they are nearing the point of maximum financial risk.

We typically opt against making predictions for the year ahead, as the trajectory of equity markets remains uncertain and highly unpredictable. Nevertheless, we observe that European equity markets are currently trading in line with long-term averages while US equity markets appear to be expensive compared to historical norms. Examining the premium of US equity markets over Europe reveals that it has reached nearly an all-time high, as shown in the chart below. Although our current strategy, ROCE Fund, focuses on European equities, if we were managing a global fund, we would likely lean towards underweighting US equities and overweighting European equities based on this observation alone.

While acknowledging that the US market traditionally commands a premium over the European market due to factors such as greater innovation, higher GDP growth, and arguably better corporate governance, we believe its current premium of 84%, is unwarranted and difficult to justify.



Source: Bloomberg. Data as of 31/12/2024. P/E based on 12-month forward data. [1] Premium US v EU calculated using the average of S&P 500 and NASDAQ P/E divided by MSCI Europe P/E.

2024 top/worst performers

TOP CONTRIBUTORS - FY 2024

	NAME	ABSOLUTE (%)
1	AMBEA AB	1.92
2	BAWAG GROUP AG	1.79
3	ACADEMEDIA	1.27

TOP DETRACTORS - FY 2024

	NAME	ABSOLUTE (%)
1	FORVIA	-2.13
2	STMICROELECTRONICS	-0.96
3	EDENRED	-0.85

Source: Bloomberg, ROCE Capital

Ambea, the leading Nordic provider of elderly and disability care services, was our top-performing holding in 2024, delivering an 86% share price appreciation. The company consistently exceeded consensus expectations in each quarterly report, particularly on margins, driven by the successful turnaround of its Vardaga and Stendi divisions. Ambea was long an overlooked and undervalued stock,

serving as a strong reminder of the importance of patience in investing. Its valuation saw a significant re-rating last year, rising from 8.5x to 11x P/E. Given this strong performance, we trimmed our position during Q4 2024, as we now see it as a less compelling risk/reward. While we still hold a position, Ambea is no longer among our top 10.

Bawag was our second-largest positive contributor, delivering a robust 84% total return. Throughout 2024, the company delivered strong results, with management maintaining a tight grip on costs, reinforcing Bawag's position as one of Europe's most efficient and profitable financial institutions. After its strong run, we saw limited further upside and recently exited our position.

Academedia, the Nordic school operator, saw a strong 34% return in 2024, making it our third-largest contributor. It was our largest position going into 2024. This strong performance was driven by good results and renewed optimism around the company's ability to weather inflation pressures. Recognizing the reduced upside potential after a strong performance, we trimmed our position during this period of strength. It is still in our top 10.

Forvia was our largest detractor in 2024, declining 56%. The auto supplier faced multiple headwinds, including weaker car demand in Europe and North America and inflationary cost pressures. Market concerns persist around its financial leverage, with net debt at approximately 2x EBITDA, given the cyclical nature of the industry and thin free cash flow margins. The recent CEO ousting by the board was a decision we welcomed. Despite the near-term challenges in the auto sector, we believe Forvia's balance sheet will improve significantly over the next 18 months. This recovery will be fueled by internal improvements, including synergies and potential asset disposals. Trading at a 2026 equity free-cash-flow yield exceeding 30%, this stock presents a compelling upside opportunity—provided it successfully executes its deleveraging strategy and meets its margin targets. We have maintained our position.

STMicroelectronics, the semiconductor company, saw its stock drop by 46% in 2024, making it our second most significant detractor for the year. The company was impacted by the ongoing global slowdown in semiconductor demand, a downturn that was particularly severe in the electric vehicle (EV) segment—an area where STMicroelectronics has substantial exposure. Compounding the issue, this slowdown coincided with excess inventory levels, further pressuring the company's top line decline in 2024. Despite these near-term headwinds, we view STMicroelectronics as a cyclical name that is likely close to trough. On normalized earnings, the stock could be trading at less than 5x EV/EBIT, suggesting significant upside potential for patient investors. We have therefore chosen to maintain our position.

Edenred, the global leader in corporate vouchers, was our third-largest detractor in 2024, with its stock declining by 37%. Market sentiment turned negative following news that the Italian government is considering capping the fees meal voucher issuers can charge restaurants and retailers at 5.0%. Edenred estimated that this regulatory change could reduce its annual EBITDA by approximately €120 million, representing nearly 10% of the group's total—an impact that took both the market and us by surprise. Despite this potential headwind, a reassuring meeting with management strengthened our confidence in the company's ability to navigate the challenge. Management remains committed to delivering 10% organic growth in 2025. Edenred now trades at a P/E of 14x, with a free cash flow yield of nearly 10% and a dividend yield of 4%. Given these attractive valuations and the company's strong fundamentals, we have chosen to maintain our position.

Sector exposure

Regarding our sector exposure, we made only minor adjustments in 2024. We slightly reduced our allocation to consumer discretionary, trimming it from 25% to 22%, by selling or taking profits on positions in **Prada**, **Watches of Switzerland**, and **Diageo**. Conversely, we modestly increased our exposure to healthcare from 7% to 9% and media/communication services from 12% to 15%, with a new position initiated in **Havas** shortly after its listing. The chart below provides a visual breakdown of our portfolio's sector exposure since inception.



	Consumer Discretionary	Healthcare	Consumer Staples	Industrials & B2B	Financials	IT	Real Estate	Communications services	Other	Cash
October 2020	14%	13%	10%	21%	7%	6%	7%	10%	8%	4%
December 2021	16%	12%	9%	19%	9%	9%	5%	14%	6%	1%
December 2022	23%	7%	10%	16%	8%	4%	4%	11%	11%	4%
December 2023	25%	7%	5%	13%	14%	7%	6%	12%	9%	1%
December 2024	22%	9%	4%	14%	13%	8%	4%	15%	12%	0%

Source: ROCE Capital

As of December 31st, 2024, ROCE Fund's portfolio included 53 positions. The portfolio aligns with our key financial criteria:

1) **Superior ROCE:** The companies in our portfolio boast a pre-tax ROCE of 21%, meaningfully above the European market average of 13%. Our primary focus is on owning businesses that efficiently utilize their capital, generating above-average returns. As Charlie Munger wrote, "*ROCE is the most important metric in evaluating the quality of a business. It separates companies that efficiently employ their capital to generate exceptional returns from those that struggle to do so*."
2) **Attractive Valuation:** With a P/E ratio of 10.6x, our portfolio screens very favorably against the European market average of 13.5x P/E and even more favorably against MSCI World that trades on 19.2x P/E. We remain committed to avoiding overpayment for quality and seek undervalued companies. This approach leads us to steer clear of trendy sectors and extreme growth companies, where valuations often fall outside our investment criteria.
3) **Low Financial Leverage:** Our net debt/EBITDA ratio of 0.5x is lower than the European market average of 1.1x. We prioritize companies with minimal or no debt, favoring those capable of

funding their growth through their free cash flow generation without straining their balance sheets. This approach helps us avoid the risks associated with permanent capital destruction, such as value-destructive M&A or rights issues.

4) **Superior Growth:** Our portfolio exhibits an average expected 12-month EPS growth of 11%, above the European market average of 5%. While we refrain from pursuing the fastest-growing companies, often too costly for us given our strict discipline on valuation, growth remains a vital criterion for us. It complements our ROCE selection process, as high returns are most beneficial when coupled with a business's ability to grow and deploy capital at elevated rates.



Source: ROCE Capital. Data as of 31/12/2024

TOP 10	Weight	Market cap	Country	Sector	Category	ROCE (pre-tax)	P/E	ND/EBITDA	EPS growth
TRIGANO SA	4.3%	€2,521m	FRANCE	Consumer Discretionary	Core	30%	7.3x	(1.0x)	7%
NEXITY	3.5%	€711m	FRANCE	Real Estate	Core	12%	NM	1.3x	(93%)
VICAT	3.4%	€1,800m	FRANCE	Materials	Opportunistic	12%	6.6x	1.9x	4%
FLATEXDEGIRO AG	3.3%	€1,791m	GERMANY	Financials	Core	22%	14.2x	(0.7x)	7%
IPSOS	3.2%	€1,945m	FRANCE	Communication Services	Core	18%	8.5x	0.3x	4%
BENETEAU	3.0%	€737m	FRANCE	Consumer Discretionary	Core	20%	14.1x	(1.0x)	5%
FUTURE PLC	2.8%	€1,186m	BRITAIN	Communication Services	Core	16%	6.0x	1.2x	12%
ACADEMEDIA AB	2.7%	€607m	SWEDEN	Consumer Staples	Opportunistic	17%	7.2x	0.7x	14%
EDENRED	2.6%	€7,891m	FRANCE	Financials	Core	30%	13.8x	1.1x	12%
ASTRAZENECA PLC	2.4%	€211,095m	BRITAIN	Health Care	Core	28%	15.2x	1.3x	12%
Median - Top 10	3.1%	€1,796m				19%	8.5x	0.9x	7%

Source: ROCE Capital. Data as of date of this report

Case studies

Below our short investment thesis on two companies that we added to the portfolio during 2024:

Forbo (Switzerland) - Market cap: €1bn - A quality cyclical at trough valuation on trough margins

Forbo is a financially robust European industrial company with a net-cash position, operating two distinct divisions: flooring products and conveyor belts, both of which are leaders in their respective markets. Its core division, flooring products, contributes 74% of total EBIT and specializes in manufacturing linoleum flooring, primarily for commercial buildings. Forbo holds a dominant position in the global linoleum flooring market, commanding over 70% market share.

Currently, the stock trades at a trough valuation, significantly below its historical norms. It is priced at 9x forward EV/EBIT (vs. a long-term median of 12x). Similarly, EV/Sales stands at 1.08x, well below the long-term median of 1.54x—clearly highlighting the valuation disparity vs. history.

Beyond valuation, the company is likely approaching its cyclical trough in margins after two challenging years of weaker demand and inflationary cost pressures. In 2024, Forbo's EBIT margin is expected to be 10.4%, compared to its long-term average of 12.2%. The last time margins were at this level was in 2010, and even during the 2009 financial crisis, its EBIT margin troughed at 7%, only to rebound by 350bps the following year.

The management team maintains a strong focus on profitability and shareholder returns, having returned 63% of the company's market cap and 100% of its cumulative free-cash-flow to shareholders over the past decade through dividends and share buybacks. Their approach mirrors that of financial owners, emphasizing long-term value creation.

Applying historical valuation multiples to future earnings suggests an upside of approximately 50%. Additionally, Forbo stands to benefit from two secular macro trends that could accelerate growth in the coming years: environmental sustainability and factory automation. These structural drivers further reinforce our conviction in the company's long-term potential.

Ryanair (Ireland) - Market cap: €22bn - The low-cost leader set for long-term dominance

Founded in 1984, Ryanair is Europe's leading low-cost airline, transporting 200 million passengers annually across 40 countries with a fleet of 600 Boeing 737s. Its business model is built on cost efficiency, flight optimization, and a standardized fleet, allowing it to offer the most competitive fares in the market, while constantly generating a Return on Capital Employed (ROCE) in excess of 25%. The low-cost segment continues to expand in Europe, steadily gaining market share from legacy airlines, which struggle to remain profitable on short-haul routes. Ryanair's durable competitive advantage lies in its low-cost structure, which is extremely difficult for competitors to replicate, solidifying its dominant position.

The company follows an aggressive expansion strategy, with large aircraft orders to increase its fleet, open new routes, and reduce fuel consumption, a key cost driver. Its strong balance sheet, with over €2 billion in net cash, sets it apart as the only airline with a sustainable shareholder return policy, including dividends and share buybacks.

Led by Michael O'Leary, one of Europe's top CEOs and a 4.5% shareholder, Ryanair trades at an attractive valuation of 11.5x 2025 P/E with a 12.5% FCF yield (before growth Capex). Its growing competitive edge positions it as the clear winner in the ongoing European airline market consolidation over the next decade.

Our ESG efforts

As an Article 8 fund, ROCE Capital is deeply committed to responsible investing, integrating ESG criteria into every stage of our decision-making process. Our active engagement policy is demonstrated by our 90%+ voting participation rate at general meetings, ensuring that we advocate for strong governance and sustainable business practices. Beyond voting, we take a proactive role in industry-wide ESG efforts. As a member of the Forum pour l'Investissement Responsable (FIR), we have actively participated in engagement dialogues with companies such as Groupe SEB and Ipsos, promoting enhanced corporate governance and sustainability initiatives.

Our commitment extends beyond financial returns. We embrace a philanthropic approach, donating 10% of our performance fees to pediatric cancer research. In 2024, this commitment resulted in a €35,000 donation to the Institut Curie, supporting innovative medical research projects that drive advancements in childhood cancer treatment.

Our development

We are excited to share the continued expansion of our team. Tom Marchi joined us as a financial analyst in May 2024, bringing strong analytical expertise and a keen focus on identifying investment opportunities.

More recently, in January 2025, Cyril Freu also joined us, bringing over 25 years of experience across both the sell-side and buy-side. Previously Cyril was a portfolio manager at DNCA, where he managed a €5 billion equity absolute return strategy. In addition to his portfolio management expertise, Cyril also served as a member of the management committee and Co-CIO at DNCA. Cyril will be launching a fund within ROCE Capital in the second half of 2025, further strengthening our investment platform. The details are currently being finalized, and we look forward to sharing more in due course.

We warmly welcome both Tom and Cyril and are confident that their expertise will contribute significantly to our continued success. As we grow, we remain committed to delivering strong results and seizing new opportunities in the evolving investment landscape.

As of year-end 2024, ROCE Fund managed €110 million in assets, marking a fivefold increase in just over four years since our inception. In 2024 alone, we collected €23 million in net inflows, demonstrating sustained investor confidence and strong capital growth. With this solid foundation, our next objective is to accelerate our expansion, rapidly scaling towards the €200 million milestone, while maintaining our disciplined investment approach and delivering long-term value to our investors.

Looking forward, we are eager to enter the next phase of our growth and would like to extend our gratitude to all our investors for their trust.

Assets Under Management growth since inception



Source: ROCE Capital.

Disclaimer: A Key Investor Information Document and a prospectus for ROCE Fund are available via the ROCE Capital website or on request and investors should consult these documents before purchasing shares in the fund. Past performance is not necessarily a guide to future performance. The value of investments and the income from them may fall as well as rise and be affected by changes in exchange rates, and you may not get back the amount of your original investment. ROCE Capital does not offer investment advice or make any recommendations regarding the suitability of its products. This document is a financial promotion and is communicated by ROCE Capital which is authorised and regulated by the AMF.